ID: ALA2391449

Max Phase: Preclinical

Molecular Formula: C20H19BrN4O3

Molecular Weight: 443.30

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(Nc2cc(C)nn(CC(=O)Nc3ccc(Br)cc3)c2=O)cc1

Standard InChI:  InChI=1S/C20H19BrN4O3/c1-13-11-18(22-15-7-9-17(28-2)10-8-15)20(27)25(24-13)12-19(26)23-16-5-3-14(21)4-6-16/h3-11,22H,12H2,1-2H3,(H,23,26)

Standard InChI Key:  PVYJAQPPAZLPCA-UHFFFAOYSA-N

Associated Targets(Human)

HL-60 67320 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

FML2_HUMAN 519 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Lipoxin A4 receptor 3472 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

fMet-Leu-Phe receptor 1/2 66 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Formyl peptide receptor 1 1372 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 443.30Molecular Weight (Monoisotopic): 442.0641AlogP: 3.71#Rotatable Bonds: 6
Polar Surface Area: 85.25Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.69CX Basic pKa: CX LogP: 2.64CX LogD: 2.64
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.61Np Likeness Score: -1.75

References

1. Giovannoni MP, Schepetkin IA, Cilibrizzi A, Crocetti L, Khlebnikov AI, Dahlgren C, Graziano A, Dal Piaz V, Kirpotina LN, Zerbinati S, Vergelli C, Quinn MT..  (2013)  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.,  64  [PMID:23685570] [10.1016/j.ejmech.2013.03.066]

Source